4-环己基丁腈 | 4441-66-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-环己基丁腈
• 英文名称: 3-cyclohexylpropionitrile
• 英文别名: 4-cyclohexylbutanenitrile；4-cyclohexyl-butyronitrile；Cyclohexyl-4-butyronitril；cyclohexanebutyronitrile
• CAS: 4441-66-1
• 化学式: C₁₀H₁₇N
• 分子量: 151.252
• InChiKey: IUQQLRKTOFNJPZ-UHFFFAOYSA-N

物化性质

• 沸点：
  132 °C(Press: 22 Torr)
• 密度：
  0.887±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  4-环己基丁腈 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 环已烷丁酸
  参考文献：
  名称：

  Francois,H. et al., Bulletin de la Societe Chimique de France, 1970, # 2, p. 617 - 624

  摘要：

  DOI：
• 作为产物：
  描述：

  4-环己基丁酰氯 在 氨 、 三氯氧磷 作用下， 生成 4-环己基丁腈
  参考文献：
  名称：

  Ketimines. III. ι-Cyclohexylalkyl Alkyl Type¹

  摘要：

  DOI：

  10.1021/ja01145a016

文献信息

• Visible Light-Induced Selective Generation of Radicals from Organoborates by Photoredox Catalysis
  作者：Yusuke Yasu、Takashi Koike、Munetaka Akita

  DOI：10.1002/adsc.201200588

  日期：2012.12.14

  A new strategy for the generation of carbon-centered radicals via oxidation of alkyl-, allyl-, benzyl- and arylborates by visible-light-driven single electron transfer (SET) photoredox catalysis has been established. The generated radicals smoothly react with TEMPO and electron-deficient alkenes to afford CO and CC coupling products, respectively. In this radical initiating system, cyclic organo(triol)borates

  碳中心自由基的生成的新策略经由通过可见光驱动单电子转移（SET）photoredox催化烷基- ，烯丙基- ，苄基-氧化arylborates和已经建立。产生的自由基与TEMPO和缺电子的烯烃平稳反应，分别提供CO和CC偶联产物。在该自由基引发体系中，环状有机（三醇）硼酸酯被证明是有用的自由基前体。
• Anodic benzylic C(sp³)–H amination: unified access to pyrrolidines and piperidines
  作者：Sebastian Herold、Daniel Bafaluy、Kilian Muñiz

  DOI：10.1039/c8gc01411f

  日期：——

  important heterocyclic motifs of pyrrolidines and piperidines within a uniform reaction protocol. The mechanism of this unprecedented C–H amination strategy involves anodic C–H activation to generate a benzylic cation, which is efficiently trapped by a nitrogen nucleophile. The applicability of the process is demonstrated for 40 examples comprising both 5- and 6-membered ring formations.

  开发了一种电化学脂肪族CH胺化策略，以在统一的反应方案中访问吡咯烷和哌啶的重要杂环基序。这种前所未有的C–H胺化策略的机制涉及阳极C–H活化以生成苄基阳离子，该阳离子被氮亲核试剂有效捕获。对于包含5元和6元环形成的40个实例证明了该方法的适用性。
• Evaluation of tributylgermanium hydride as a reagent for the reductive alkylation of active olefins with alkyl halides
  作者：Philip Pike、Susan Hershberger、James Hershberger

  DOI：10.1016/s0040-4020(01)89817-3

  日期：——

  general low reactivity towards alkyl halide substrates. The following series of six other triorganotin and triorganogermanium hydrides were also briefly screened for possible application to reductive alkylations: trimesityltin hydride, trimesitylgermanium hydride, triphenyltin hydride, triphenylgermanium hydride, trineopentyltin hydride, and tricyclohexylgermanium hydride.

  系统地评估了使用氢化三丁基锗的烷基卤化物对丙烯腈和2-环己烯-1-酮的还原烷基化作用。将锗试剂的性能与更常用的氢化三丁基锡的性能进行了比较。对于某些应用，锗试剂在不使用大量过量烯烃的情况下提供了提高的产率。锗试剂的缺点包括倾向于使氢锗甲酸酯化活性末端烯烃和对烷基卤化物底物的反应性普遍较低。还简要筛选了以下六个其他系列的三有机锡和三有机锗氢化物，以用于可能的还原烷基化反应：氢化三苯甲醇，氢化三苯锗锗，氢化三苯锡，三苯锗氢化物，三烯丙基酪蛋白氢化物，
• Synthesis and Antiallergy Activity of (1,3,4)Thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(3H)-one Derivatives. II. 6-Alkyl- and 6-Cycloalkylalkyl Derivatives.
  作者：Shuichi YOKOHAMA、Tamotsu MIWA、Shunzo AIBARA、Hiroyuki FUJIWARA、Hiroo MATSUMOTO、Kiyoshi NAKAYAMA、Teiji IWAMOTO、Mikiko MORI、Reimei MOROI、Wataru TSUKADA、Sumiro ISODA

  DOI：10.1248/cpb.40.2391

  日期：——

  A series of 6-alkyl- or 6-(cycloalkylalkyl)-[1,3,4]thiadiazolo[3,2- a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-ones 1b--o was synthesized from the corresponding 1,3,4-thiadiazol-5-amines 3b--o and the antiallergic activities of the products were evaluated. Among the compounds 6-(2-cyclohexylethyl)- [1,3,4]thiadiazolo[3,2-a]-1,2,3-triazolo[4,5-d]pyrimidin-9(3H)-one 1h, whose X-ray crystallographic stereostructure

  一系列的6-烷基或6-（环烷基烷基）-[1,3,4]噻二唑[3,2-a] -1,2,3-三唑[4,5-d]嘧啶-9（3H） -由相应的1,3,4-噻二唑-5-胺3b-o合成1b-o，并评估产物的抗过敏活性。在化合物6-（2-环己基乙基）-[1,3,4]噻二唑[3,2-a] -1,2,3-三唑并[4,5-d]嘧啶-9（3H）-1h中发现其X射线晶体学立体结构是一种有前途的新型抗过敏药，具有低毒性和双重活性，可作为白三烯D4受体拮抗剂和口服活性肥大细胞稳定剂。
• [EN] 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS<br/>[FR] UTILISATION DE DERIVES AMIDES D'ACIDE 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIQUE COMME INHIBITEURS DE LA PHOSPHOLIPASE
  申请人：LILLY CO ELI

  公开号：WO2004093872A1

  公开（公告）日：2004-11-04

  The present invention provides a compound of formula I (1) wherein; R, is selected from the group consisting of C5-C13alky1;:C,-C,2haloalkyl, C4­C,2alkenyl, C4-C12alkynyl, or C,- C5alkylcycloalkyl, C3-C8cycloalkyl, C,­ C5alkylheterocyclic, and aryl, wherein the, cycloalkyl, cycloalkenyl, heterocyclic and aryl substituents are optionally substituted with onf to three substituents independently selected from C,-C8a)kyl, C,-C8haloalkyl,`C2-CBalkenyl, C2-C8a)kynyl, phenyl, benzyl, hydroxy, C,-C5 alkoxy, (C}12)m000C,-Csalkyl, (CH2)mNRaRb, and C,­C4alkylcycloalkyl; wherein Wand Rb are independently selected from hydrogen, C,­CBalkyl, C2-CBalkenyl, C2-CBalkynyl, and C,- C5alkylcycloalkyl; R2 is hydrogen; R3, R4, R5, and R6, are independently selected from hydrogen, C,-C12alkyl, C2­C,2haloalkyl, C2-C,2 alkenyl, C2-C12alkynyl, C,-Ct2alkylaryl, C,-C12alkylcyclohexyl, C,­ C12alkylcyclopentyl, C,-C1zalkylheterocyclic, (CH2)m000H, (CH2)mC0(C,-C,o)alkyl, (CH2)m COO(C,-C,o)alkyl, (CH2)mCOO(C,-C,o)alkylaryl, C,-C,oalkylamino, halo, (CH2)mCONH2, (CH2)rCONRaRb, phenyl, or aryl wherein each of the phenyl or aryl groups is optionally substituted with one to three groups independently selected from CBalkyl, C,-CBhaloalkyl, C2-CBalkenyl, CZ CBalkynyl, phenyl, benzyl, hydroxy, C,-C5 alkoxy, (CH2)m000C,-Csalkyl, and C,-C4alkylcycloalkyl; and wherein m is 0, 1, 2, or 3; R7 is selected from the group consisting of hydrogen, C,-Cloalkyl, C,­C,ohaloalkyl, C2-C,oalkenyl, C2-C,oalkynyl, C,-C6alkylaryl, C,-C6alkylcyclohexyl, C - C6aikylcyclopentyl, C,-C6alkylheterocyclic, or aryl; or a pharmaceutically acceptable sal lvate thereofi together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.

  本发明提供了一种式子I（1）的化合物，其中R选自C5-C13烷基，C3-C12卤代烷基，C4-C12烯基，C4-C12炔基，或C1-C5烷基环烷基，C3-C8环烷基，C1-C5烷基杂环，和芳基，其中环烷基，环烯基，杂环和芳基取代基可选择地独立地被C1-C8烷基，C1-C8卤代烷基，C2-C8烯基，C2-C8炔基，苯基，苄基，羟基，C1-C5烷氧基，（C12）m000C1-C5烷基，（CH2）mNRaRb和C1-C4烷基环烷基取代，其中W和Rb独立地选择氢，C1-C6烷基，C2-C6烯基，C2-C6炔基和C1-C5烷基环烷基；R2为氢；R3、R4、R5和R6独立地选择氢，C1-C12烷基，C2-C12卤代烷基，C2-C12烯基，C2-C12炔基，C1-C12烷基芳基，C1-C12烷基环己基，C1-C12烷基环戊基，C1-C12烷基杂环，（CH2）m000H，（CH2）mCO（C1-C4）烷基，（CH2）mCOO（C1-C4）烷基，（CH2）mCOO（C1-C4）烷基芳基，C1-C4烷基氨基，卤素，（CH2）mCONH2，（CH2）rCONRaRb，苯基或芳基，其中苯基或芳基中的每个取代基可选择地独立地被C1-C8烷基，C1-C8卤代烷基，C2-C8烯基，C2-C8炔基，苯基，苄基，羟基，C1-C5烷氧基，（C12）m000C1-C5烷基和C1-C4烷基环烷基取代；其中m为0、1、2或3；R7选自氢，C1-C6烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6烷基芳基，C1-C6烷基环己基，C1-C6烷基环戊基，C1-C6烷基杂环或芳基；或其药学上可接受的盐；以及使用这样的化合物来抑制肝脏脂肪酶和/或内皮脂肪酶活性，用于治疗、缓解或预防肝脏脂肪酶和/或内皮脂肪酶介导的疾病。

表征谱图